LCKLSL;
LCKLSL 是一种 N 末端六肽，是一种竞争性的膜联蛋白 A2 (AnxA2) 抑制剂，可有效抑制组织纤溶酶原激活物 (tPA) 与 AnxA2 的结合。LCKLSL 还可抑制纤溶酶的产生，并具有抗血管生成的作用。
LCKLSL Chemical Structure
CAS No. : 533902-29-3
| 规格 | 价格 | 是否有货 | |
|---|---|---|---|
| 5 mg | ￥2500 | 询问价格 货期 | |
| 10 mg | ￥4500 | 询问价格 货期 | |
| 25 mg | ￥8500 | 询问价格 货期 | |
* Please select Quantity before adding items.
LCKLSL 的其他形式现货产品:
| 生物活性 |
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1]. |
IC50 Target |
Annexin A2 (AnxA2)[1] |
|---|---|
| 体外研究 (In Vitro) |
In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 体内研究 (In Vivo) |
Application of LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) of angiogenesis demonstrates suppression of the angiogenic responses. Treatment with the LCKLSL peptide significantly decreases the vascular length. At a dose of 5 μg/mL, the LCKLSL peptide significantly decreases the number of vascular branches, junctions and end-points[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 分子量 |
675.88 |
| Formula |
C30H57N7O8S |
| CAS 号 |
533902-29-3 |
| Sequence |
Leu-Cys-Lys-Leu-Ser-Leu |
| Sequence Shortening |
LCKLSL |
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 参考文献 |
|